Novel micropeptide HMBJ and application thereof
By discovering and verifying the endogenous coding function of the new micropeptide HMBJ, the problem of lack of organ fibrosis-related micropeptides in the existing technology is solved, and the significant inhibitory effect on organ fibrosis cells is achieved, providing a new direction for treatment. .
Patent Information
- Application Number
- CN202310539447.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-15
- Publication Date
- 2024-11-15
AI Technical Summary
No micropeptides associated with organ fibrosis have been found in the prior art, making it difficult to effectively diagnose and treat the disease.
The novel micropeptide HMBJ was discovered and encoded, and the endogenous coding function was verified by analyzing lncRNA and ORF sequences, using gene editing, immunoprecipitation and LC-MS/MS, and preparing drugs for therapeutic or auxiliary treatment of organ fibrosis through recombinant vectors. .
The novel micropeptide HMBJ significantly inhibits key indicators in the organ fibrosis cell model, such as the type I collagen α1 chain gene, transforming growth factor β1 and connective tissue growth factor, expanding the treatment spectrum and providing new ideas for the development of organ fibrosis drugs.
Smart Images

Figure CN118955674A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of biomedicine, and specifically relates to a novel micropeptide HMBJ, lncRNA and / or ORF encoding the novel micropeptide HMBJ, and their application in diagnosis or auxiliary diagnosis, treatment or auxiliary treatment of fibrosis of various organs. Background Art
[0002] Long non-coding RNA (lncRNA) refers to a functional RNA molecule that consists of a length of more than 200 nucleotides and is considered to be unable to be translated into proteins. Existing studies have shown that lncRNA plays an important role in epigenetic regulation, cell cycle and differentiation regulation, and is involved in major human health diseases including cancer and degenerative neurological diseases. With the rapid development of molecular biology, computational biology and deep sequencing technology, a large number of non-classical short open reading frames (ORFs) that were previously unannotated and hidden in long non-coding RNAs actually have the function of encoding functional proteins. Micropeptides are a type of translation product encoded by short open reading frames (sORFs) with a length of 2 to 100 codons.
[0003] Organ fibrosis refers to a fibrotic disease that can occur in multiple organs. The main pathological changes are an increase in fibrous connective tissue and a decrease in parenchymal cells in the organ tissue. Persistent fibrotic lesions occurring in organs can destroy the organ structure and function, further leading to organ failure and malignant tumors. It is considered to be a tumor-like lesion between benign and malignant, which seriously threatens human health and life.
[0004] The discovery and study of organ fibrosis-related micropeptides is of great significance for the development of novel and effective disease diagnosis and treatment, and can provide important reference and development value for exploring new application areas. However, there are currently no reports on micropeptides in the field of organ fibrosis research. Summary of the invention
[0005] 1. Purpose of the Invention
[0006] One of the purposes of the present application is to provide a lncRNA and a nucleotide sequence thereof, which is lowly expressed in organ fibrosis cells and / or tissues.
[0007] The second purpose of the present application is to provide an ORF and its nucleotide sequence, wherein the ORF sequence is located in the above-mentioned lncRNA and can encode a novel micropeptide HMBJ.
[0008] The third purpose of the present application is to provide a novel micropeptide HMBJ and its amino acid sequence. The novel micropeptide HMBJ is a completely new endogenous human polypeptide discovered for the first time.
[0009] The fourth object of the present application is to provide the use of the above-mentioned lncRNA in the preparation of a diagnostic or auxiliary diagnostic reagent for organ fibrosis and / or the preparation of a therapeutic or auxiliary therapeutic drug for organ fibrosis.
[0010] The fifth object of the present application is to provide the use of the ORF sequence in the above-mentioned lncRNA in the preparation of a diagnostic or auxiliary diagnostic reagent for organ fibrosis and / or the preparation of a therapeutic or auxiliary therapeutic drug for organ fibrosis.
[0011] The sixth object of the present application is to provide the use of the novel micropeptide HMBJ or the nucleotide encoding the novel micropeptide HMBJ in the preparation of drugs for treating or assisting in the treatment of organ fibrosis.
[0012] 2. Technical solution
[0013] In order to achieve the above-mentioned invention object, the technical solution adopted in this application is as follows:
[0014] The present application provides a lncRNA molecule ENSG00000272654, whose nucleotide sequence is shown in SEQ ID NO.1. The applicant analyzes multiple organ fibrosis high-throughput sequencing data and finds for the first time that the lncRNA molecule ENSG00000272654 has an important relationship with organ fibrosis, specifically, it is lowly expressed in multiple organ fibrosis cells and / or tissues, and there are currently no related research reports.
[0015] The present application also provides the open reading frames (ORF) of the above-mentioned lncRNA molecule ENSG00000272654, whose nucleotide sequence is shown in SEQ ID NO.2. The applicant analyzed the translation characteristics of the open reading frame of the lncRNA molecule ENSG00000272654 and found that it has the potential to encode functional proteins. By using methods including gene editing, immunoprecipitation and LC-MS / MS to verify endogenous coding, it was confirmed that the lncRNA molecule ENSG00000272654 has a coding sequence (ORF), and the sequence has not been reported anywhere.
[0016] The present application also provides a novel micropeptide HMBJ, whose amino acid sequence contains the sequence shown in SEQ ID NO.3, which is encoded by human lncRNA ENSG00000272654 and is a completely new human endogenous polypeptide discovered for the first time.
[0017] The present application also provides a nucleotide encoding the novel micropeptide HMBJ. The nucleotide sequence is not limited to the lncRNA molecule ENSG00000272654 or the ORF contained therein. Those skilled in the art know that the corresponding nucleotide sequence can be designed according to the amino acid sequence of the novel micropeptide HMBJ.
[0018] The present application also provides a recombinant vector, which includes the above-mentioned nucleotide sequence encoding the novel micropeptide HMBJ. The recombinant vector can be a plasmid, a viral vector, or other vector known to those skilled in the art.
[0019] The present application also provides the use of the above-mentioned novel micropeptide HMBJ, nucleotides encoding the novel micropeptide HMBJ, and recombinant vectors in the preparation of drugs for treating or assisting the treatment of organ fibrosis. The applicant has found through verification that the novel micropeptide HMBJ has a significant inhibitory effect on organ fibrosis cell models and can be used to treat or assist in the treatment of organ fibrosis.
[0020] Furthermore, the above-mentioned organ fibrosis includes liver fibrosis, kidney fibrosis and / or lung fibrosis, etc.
[0021] The present application also provides the use of the above-mentioned lncRNA molecule ENSG00000272654 and / or the ORF contained therein in the preparation of a reagent for diagnosing or assisting in diagnosing organ fibrosis.
[0022] Furthermore, the above-mentioned diagnostic or auxiliary diagnostic reagent for organ fibrosis includes primers for specifically amplifying the lncRNA molecule ENSG00000272654 or the ORF contained therein.
[0023] Furthermore, the above-mentioned specific primer pair contains the following nucleotide sequence:
[0024] F:CAAGGGATGGAGGCGAAACT;
[0025] R:CCACAGTGCTGGTCAAGTCA.
[0026] Furthermore, the above-mentioned organ fibrosis includes liver fibrosis, kidney fibrosis and / or lung fibrosis.
[0027] The present application also provides a pharmaceutical composition for treating or assisting in the treatment of organ fibrosis, which contains at least the novel micropeptide HMBJ, or the novel micropeptide HMBJ encoding nucleotide, or the recombinant vector, and a pharmaceutically acceptable carrier.
[0028] The present application also provides a kit for diagnosing or assisting in the diagnosis of organ fibrosis, which includes primers for specifically amplifying the lncRNA molecule ENSG00000272654 or the ORF contained therein.
[0029] Furthermore, the above-mentioned specific primer pair contains the following nucleotide sequence:
[0030] F:CAAGGGATGGAGGCGAAACT;
[0031] R:CCACAGTGCTGGTCAAGTCA.
[0032] 3. Beneficial effects
[0033] Compared with the prior art, the present application has the following beneficial effects:
[0034] (1) The present application provides a lncRNA and its nucleotide sequence. By analyzing multiple organ fibrosis sequencing data, it is found that the lncRNA molecule ENSG00000272654 is lowly expressed in organ fibrosis. Through literature search, no related research reports are found. It can be used for diagnosis or auxiliary diagnosis, treatment or auxiliary treatment of organ fibrosis, or for the preparation of diagnosis or auxiliary diagnosis, treatment or auxiliary treatment of organ fibrosis reagents.
[0035] (2) The present application provides a nucleotide sequence of an open reading frame of a lncRNA, which can encode a novel micropeptide HMBJ. After searching the database (BLAST, UniProt) and literature, no protein or polypeptide fragment with a homologous sequence to the micropeptide HMBJ was found. The nucleotide sequence can be used to encode and generate a novel micropeptide HMBJ, or to diagnose or assist in the diagnosis, treatment or auxiliary treatment of organ fibrosis, or to prepare a reagent for the diagnosis, auxiliary diagnosis, treatment or auxiliary treatment of organ fibrosis.
[0036] (3) The present application provides a novel micropeptide HMBJ with a completely new amino acid sequence. After searching the database (BLAST, UniProt) and literature, no protein or polypeptide fragment with a homologous sequence to the micropeptide HMBJ was found. The novel micropeptide HMBJ is composed of 71 amino acids. The synthetic peptide of the micropeptide HMBJ has a significant inhibitory effect on key indicators of human liver fibrosis, renal fibrosis and pulmonary fibrosis in vitro, including type I collagen α1 chain gene (Col1a1), transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF). The novel micropeptide HMBJ can also be used as a therapeutic drug for fibrosis of other organs, which greatly expands the therapeutic spectrum of the micropeptide and provides a new idea for the development of drugs for organ fibrosis.
[0037] (4) The present application uses a solid phase synthesis method to obtain a synthetic peptide of a novel micropeptide HMBJ based on the amino acid sequence of the novel micropeptide HMBJ, and the method mainly includes peptide synthesis, peptide purification, peptide purity detection and mass spectrometry identification; by constructing three organ fibrosis cell models, for example, 10 nmol of recombinant human TGFβ1 (Peprotech) stimulating factor and different concentrations of synthetic peptides of the micropeptide HMBJ are added to human hepatic stellate cells LX-2, human non-small cell lung cancer cell line A549 and human renal proximal tubule cells HK2, respectively, and after incubation for 24 hours, the total RNA of the collected cell samples is extracted using TRIzol reagent, and then the extracted total RNA is reverse transcribed using a reverse transcription reagent, and the mRNA expression of genes Col1a1, TGFβ1 and CTGF in the three organ fibrosis cell models is detected using real-time fluorescence quantitative PCR method. The results show that the synthetic peptide of the micropeptide HMBJ has a significant inhibitory effect on the three organ fibrosis cell models. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 To analyze the volcano plot of low expression of ENSG00000272654 in organ fibrosis using differential analysis;
[0039] Figure 2 Sanger sequencing of monoclonal cells using gene editing to insert the Flag tag into the micropeptide HMBJ;
[0040] Figure 3 To detect the expression of the target band of micropeptide HMBJ using immunoprecipitation method;
[0041] Figure 4 Protein spectrum for detecting micropeptide HMBJ using LC-MS / MS method;
[0042] Figure 5 The melting curves of primers for fibrosis genes in four organs were tested using the qPCR method;
[0043] Figure 6 To detect gene indicators in human liver fibrosis cell model using qPCR method;
[0044] Figure 7 To detect gene indicators constructed in human renal fibrosis cell model using qPCR method;
[0045] Figure 8 To detect gene indicators constructed in human pulmonary fibrosis cell model using qPCR method;
[0046] Fig. 9 This is the liquid phase result diagram of the micropeptide HMBJ synthetic peptide;
[0047] Fig.10 This is the mass spectrometry result of the micropeptide HMBJ synthetic peptide;
[0048] Fig.11 To detect the inhibitory effect of micropeptide HMBJ in human liver fibrosis cell model using qPCR method;
[0049] Fig.12 To detect the inhibitory effect of micropeptide HMBJ in human renal fibrosis cell model using qPCR method;
[0050] Fig.13 The qPCR method was used to detect the inhibitory effect of micropeptide HMBJ in a human pulmonary fibrosis cell model. DETAILED DESCRIPTION
[0051] The present application is further described below in conjunction with specific embodiments.
[0052] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs; the term "and / or" used herein includes any and all combinations of one or more of the associated listed items.
[0053] If no specific conditions are specified in the examples, the experiments were carried out according to conventional conditions or conditions provided by the manufacturer. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0054] As used herein, the term "about" is used to provide flexibility and imprecision associated with a given term, measurement or value. The degree of flexibility for a particular variable can be easily determined by one skilled in the art.
[0055] As used herein, the term "at least one of" is intended to be synonymous with "one or more of." For example, "at least one of A, B, and C" expressly includes only A, only B, only C, and combinations of each thereof.
[0056] Concentration, amount and other numerical data can be presented in range format herein.It should be understood that such range format is only used for convenience and simplicity, and should be flexibly interpreted as not only including the numerical value clearly described as range limit, but also including all single numerical values or sub-ranges contained in the range, just as each numerical value and sub-range are clearly described.For example, the numerical range of about 1 to about 4.5 should be interpreted as not only including the limit value of 1 to about 4.5 clearly described, but also including single numerals (such as 2,3,4) and sub-ranges (such as 1 to 3,2 to 4, etc.).The same principle is applicable to the scope of only narrating a numerical value, such as "less than about 4.5", which should be interpreted as including all the above-mentioned values and ranges.In addition, no matter how the breadth of the described range or feature is, this explanation should be applicable.
[0057] In an embodiment, the method for validating the endogenous encoding of micropeptide HMBJ includes gene editing, immunoprecipitation and LC-MS / MS, specifically including:
[0058] A Flag tag was correctly inserted at the genomic location of the micropeptide HMBJ using a gene editing approach;
[0059] Immunoprecipitation combined with chemiluminescence was used to observe the generation of the target band;
[0060] Protein profile of micropeptide HMBJ detected using LC-MS / MS method.
[0061] In an embodiment, the real-time fluorescence quantitative PCR method is used to detect gene indicators in the organ fibrosis cell model, specifically including:
[0062] Human hepatic stellate cells LX-2, human non-small cell lung cancer cell line A549 and human renal proximal tubule cells HK2 were plated and different concentrations of recombinant human TGFβ1 (Peprotech) stimulatory factor were added;
[0063] After continuous stimulation for 24 h and 48 h, respectively, the mRNA expression of genes Col1a1 and α-SMA was detected by real-time fluorescence quantitative PCR to determine whether the cell model was successfully constructed.
[0064] In the embodiment, a novel micropeptide HMBJ is obtained by solid phase synthesis, and the quality inspection of the synthetic peptide is carried out, specifically including:
[0065] The peptide resin synthesis includes decapping with hexahydropyridine / N, N-dimethylformamide (DMF) decapping solution, washing the resin with DMF, then adding a condensing agent to fully react in a reactor, and finally washing the resin with DMF to clean the by-products;
[0066] Add lysis buffer to fully cleave the peptide, and use a sand core funnel to separate the resin from the peptide;
[0067] Anhydrous ether was added to precipitate the polypeptide, the supernatant was discarded by centrifugation, the polypeptide was washed with anhydrous ether, and the polypeptide was dried to obtain a crude polypeptide;
[0068] The crude peptide was dissolved in deionized water, filtered, and purified by semi-preparative HPLC;
[0069] The purity of the peptide was checked by analytical RP-HPLC.
[0070] In an embodiment, the method of using real-time fluorescence quantitative PCR to detect the inhibitory effect of micropeptide HMBJ in a fibrotic cell model includes:
[0071] Human hepatic stellate cells LX-2, human non-small cell lung cancer cell line A549, or human renal proximal tubule cells HK2 were counted and plated;
[0072] Except for the blank group, 10 nmol of recombinant human TGFβ1 (Peprotech) stimulatory factor was added and the stimulation lasted for 24 h;
[0073] TRIzol reagent was used to extract the total RNA of the collected cell samples, and the extracted total RNA was reverse transcribed using a reverse transcription reagent, and then qPCR reaction was performed using a qPCR premix solution;
[0074] Real-time fluorescence quantitative PCR instrument was used to detect the mRNA expression of genes Col1a1, TGFβ1 and CTGF.
[0075] Example 1
[0076] In this example, the expression level of gene ENSG00000272654 in fibrosis of various organs was analyzed.
[0077] The NCBI and ENA databases were searched with the keywords "fibrosis" and "Homo sapiens" and Aspera commands were used to batch download high-throughput sequencing data related to fibrosis in various organs, including human liver fibrosis and normal cell data (accession number: PRJNA638727), human liver fibrosis patient and healthy tissue data (accession number: PRJEB27201), human kidney fibrosis and normal cell data (accession number: GSE23338), and human lung fibrosis patient and healthy tissue data (accession number: PRJNA878759). The downloaded sequencing data were then processed and analyzed. First, the Fastp software package (v0.18.0) was used to filter out the reads containing adapter sequences and low-quality bases in the original data. The Bowtie software package (v1.3.0) was then used to align the data with human tRNA and rRNA sequences. The unaligned data were aligned with the human reference genome (GRCh38.Ensembl98) using the HISAT2 software package (v2.2.1). Finally, the reads with a successful alignment rate greater than 90% were used as subsequent analysis data. The genes and transcripts in the data were then assembled and quantified using the StringTie software package (v1.2.2). The differential gene expression analysis was then performed using the DESeq2 software package (v1.38.3). The results showed that the significance padj of gene ENSG00000272654 was <0.05 and the difference multiple (log2FoldChange) was <-1, indicating that the gene is at a low expression level in multiple organ fibrosis. Expression differences such as Figure 1 shown.
[0078] Example 2
[0079] In this example, the coding capacity of the micropeptide HMBJ was endogenously tested, including gene editing, immunoprecipitation, and LC-MS / MS.
[0080] The gene sequence of ENSG00000272654 was downloaded from the Ensembl database, and the corresponding sgRNA plasmid and the donor fragment containing the Flag tag were designed. The sgRNA plasmid and the donor fragment were introduced into 293T cells using the lipo3000 liposome transfection reagent, and the fluorescence was observed 48 hours after transfection. The cells were collected by trypsin digestion, centrifuged and discarded the supernatant, and the cells were resuspended in basal medium for flow sorting. The sorted cells were counted and then monoclonal plating and Sanger sequencing were performed to screen out monoclonal cells with the Flag tag correctly inserted, such as Figure 2 shown.
[0081] The cells were rinsed twice with PBS and collected by trypsin digestion. After centrifugation and discarding the supernatant, the cell pellet was resuspended in RIPA lysis buffer. After lysis on ice for 30 minutes, the supernatant was collected by centrifugation at 12000g for 15 minutes, and Flag antibody and agarose gel were added to form a protein-antibody-gel complex. After centrifugation at 6000g for 1 minute to remove the gel, 1×SDS loading buffer was added, mixed and boiled for denaturation for 10 minutes. The total protein was separated by 12% SDS-PAGE gel and transferred to a PVDF membrane, and then 5% skim milk powder was added for blocking at room temperature for 3 hours, and TBST was washed 5 times for 10 minutes each time. After adding the Flag first antibody and incubating at 4°C overnight, TBST was washed 5 times for 10 minutes each time. The second antibody was incubated at room temperature for 1 hour, and TBST was washed 5 times for 10 minutes each time. ECL ultra-sensitive chemiluminescent solution was added for development, and the Tannon imaging system was used to detect whether the target band was produced. The results are shown as follows. Figure 3 shown.
[0082] In order to further prove the coding ability of the micropeptide HMBJ, the SDS-PAGE gel containing the target protein in the above step was stained with Coomassie Brilliant Blue, and the target band visible to the naked eye was cut and detected by LC-MS / MS (liquid chromatography tandem quadrupole mass spectrometry) to obtain the mass spectrometry results of the target micropeptide, as shown in Figure 4 shown.
[0083] Through gene editing, immunoprecipitation and mass spectrometry detection, it was found that after the Flag tag was inserted into the genomic sequence of the target micropeptide, the target band and mass spectrometry peptide segment of the micropeptide HMBJ appeared, which fully proved that the new micropeptide HMBJ has the ability of endogenous encoding.
[0084] Example 3
[0085] In this example, real-time fluorescence quantitative PCR method was used to detect gene indexes in three organ fibrosis cell models.
[0086] (1) Primer design
[0087] The key indicators of the organ fibrosis cell model include type I collagen α1 chain gene (Col1a1), transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF). Primer Premier 5.0 was used to design the corresponding primers, including Col1a1 upstream and downstream primers, TGFβ1 upstream and downstream primers, CTGF upstream and downstream primers, and α-SMA upstream and downstream primers. According to the instructions for use of Life Invitrogen's TRIzol reagent, the total RNA of the collected cell samples was extracted, and the purity and concentration of the extracted RNA were quantified using the NanoDrop 2000 ultra-micro spectrophotometer. Agarose quality inspection ensured the integrity of the extracted RNA. Reverse transcription reagent was used After reverse transcription of the extracted total RNA using III RT SuperMix for qPCR (+gDNAwiper), qPCR reaction was performed using qPCR premix ChamQ SYBR qPCR Master Mix. The reaction system is as follows:
[0088] Table 1 qPCR reaction system
[0089]
[0090] After mixing the above components evenly, follow the following procedure: pre-denaturation at 95°C for 30s, 95°C for 10s, 60°C for 30s, and 50 cycles. After the qPCR reaction is completed, collect the Cq value of each sample well, and the maximum error of the Cq value between the three replicate wells of the sample is ≤0.5 to ensure the accuracy of the data, and observe whether the melting curve of the designed primer is a single peak to judge the specificity of the reaction. Figure 5 shown.
[0091] (2) Model construction
[0092] Human hepatic stellate cells LX-2, human non-small cell lung cancer cell line A549, and human renal proximal tubule cells HK2 were cultured in a cell culture incubator at 37°C and 5% CO2 until the cell density was above 80%. The cells were collected by trypsin digestion, centrifuged and discarded the supernatant, and then resuspended in complete medium and counted by cell counter. The cell concentration was adjusted to 1.5×10 5 After the cells reached 400 μg / mL, they were inoculated into a six-well cell culture plate and placed in a cell culture incubator at 37°C and 5% CO2 for further culture. After 24 hours of cell culture, the culture medium was removed and different concentrations of recombinant human TGFβ1 (Peprotech) stimulatory factors were added. After continuous stimulation for 24 hours and 48 hours, the mRNA expression of genes Col1a1 and α-SMA was detected by qPCR method. Figure 6 , 7 , as shown in Figure 8.
[0093] Example 4
[0094] In this example, the micropeptide HMBJ was obtained by solid phase synthesis, and the quality of the synthesized micropeptide was tested.
[0095] In this embodiment, the peptide solid phase synthesis method is used to synthesize the micropeptide HMBJ, the synthesized micropeptide HMBJ is separated and purified by preparative HPLC, and the purity of the micropeptide HMBJ is determined by analytical RP-HPLC. The peptide solid phase synthesis method uses Fmoc-Thr-wang-resin as the starting material, and then uses protected amino acids to couple to the last amino acid of the target sequence in sequence. After the coupling work is completed, the crude polypeptide is fully washed, cracked, and post-treated to obtain a crude polypeptide. After the crude product is dissolved, it is purified, concentrated, and freeze-dried using a preparative high performance liquid phase to obtain a pure polypeptide. The specific reaction steps are as follows:
[0096] (1) Peptide resin synthesis
[0097] Weigh 1mmol Fmoc-Thr-wang-resin, pour it into a glass sand core reaction column, and add 20ml CH2Cl2 to fully swell the resin.
[0098] a. Decapping: Add 20 ml of decapping solution of 20% hexahydropyridine / N,N-dimethylformamide (DMF), drain the decapping solution after a period of reaction, wash once with DMF, and then add 20 ml of decapping solution to react and remove the Fmoc protecting group;
[0099] b. Washing: Drain the decapping solution and wash the resin with DMF to fully remove the by-products;
[0100] c. Condensation: The protected amino acid and activator for coupling are dissolved in DMF and a condensing agent, and reacted fully in a reactor;
[0101] d. Washing: Drain the reaction solution and thoroughly wash the resin with DMF to remove by-products.
[0102] (2) Cracking
[0103] The drained resin was placed in a conical flask, and a lysis solution was added to fully lyse the combined polypeptide. The resin and the polypeptide were separated using a sand core funnel. The components of the lysis solution and the volume composition of each component were: trifluoroacetic acid: phenol: water: thioanisole: EDT = 90: 3: 3: 2: 2.
[0104] (3) Post-processing
[0105] The lysate was added to anhydrous ether after ice bath, and the polypeptide was precipitated by slow stirring. After centrifugation and the supernatant was discarded, the polypeptide was washed with anhydrous ether and dried to obtain the crude polypeptide.
[0106] (4) Purification
[0107] a. Dissolution: Dissolve the crude polypeptide in deionized water and filter it with a filter membrane with a pore size of 0.45 μm.
[0108] b. Preparation: Purification was performed by semi-preparative HPLC, mobile phase: A was 0.1% TFA (acetonitrile), B was 0.1% TFA (water), the purification system was as follows:
[0109] Table 2 Peptide purification system
[0110]
[0111] The solution at an ultraviolet wavelength of 220 nm was collected, and the molecular weight was confirmed to be consistent with the theoretical value by MS. The purity of the solution was greater than 95% by HPLC analysis. The qualified solution was concentrated under reduced pressure at 37°C using a rotary evaporator to remove the organic solvent, and then placed in a freeze-drying plate and frozen at -80°C, and then freeze-dried using a freeze dryer to obtain a pure polypeptide.
[0112] (5) Purity testing
[0113] The purified product after freeze-drying was collected and the peptide purity was tested by analytical RP-HPLC. The analysis conditions were: mobile phase: 0.1% TFA (acetonitrile), 0.1% TFA (water); sample volume: 10 μL, and the specific reaction system was as follows:
[0114] Table 3 Purity detection system
[0115]
[0116] The synthesized peptide was analyzed by reversed phase liquid chromatography for purity identification. The results showed that the purity of the prepared micropeptide HMBJ reached 95.86%, which is greater than 95%. Fig. 9 , as shown in 10, it meets the requirements of subsequent experiments. The specific information is as follows:
[0117] Table 4 Purity test results
[0118]
[0119] Example 5
[0120] In this example, the inhibitory effect of the micropeptide HMBJ on the human liver fibrosis cell model was detected. Human hepatic stellate cells LX-2 were cultured in a cell culture incubator at 37°C and 5% CO2 until the cell density was above 80%, and then the cells were collected by trypsin digestion. After centrifugation and discarding the supernatant, the cells were resuspended in complete medium and counted by a cell counter. The cell concentration was adjusted to 1.5×10 5After the cells were inoculated into six-well cell culture plates at 37°C and 5% CO2, they were cultured in a cell culture incubator. After 24 hours of cell culture, the culture medium was removed, and 2‰ DMSO solvent was added as a negative control, 20μmol of Hydronidone was added as a positive control, and the remaining groups were added with 40μmol, 10μmol, 2.5μmol, 625nmol and 156nmol of synthetic peptide HMBJ in equal proportions as the drug-dosing group. Half an hour later, except for the blank control, the remaining groups were added with 10nmol of recombinant human TGFβ1 (Peprotech) stimulating factor. After 24 hours of continuous stimulation, the mRNA expressions of genes Col1a1, TGFβ1 and CTGF were detected, as shown in Figure 2. Fig.11 shown.
[0121] Example 6
[0122] In this example, the inhibitory effect of the micropeptide HMBJ on the human renal fibrosis cell model was detected.
[0123] Human renal proximal tubular cells HK2 were cultured in a cell culture incubator at 37°C and 5% CO2 until the cell density was above 80%. The cells were collected by trypsin digestion, centrifuged and discarded the supernatant. The cells were resuspended in complete medium and counted using a cell counter. The cell concentration was adjusted to 1.5×10 5 After the cells were inoculated into six-well cell culture plates at 37°C and 5% CO2, they were cultured in a cell culture incubator. After 24 hours of cell culture, the culture medium was removed, and 2‰ DMSO solvent was added as a negative control, 20μmol of Hydronidone was added as a positive control, and the remaining groups were added with 40μmol, 10μmol, 2.5μmol, 625nmol and 156nmol of synthetic peptide HMBJ in equal proportions as the drug-dosing group. Half an hour later, except for the blank control, the remaining groups were added with 10nmol of recombinant human TGFβ1 (Peprotech) stimulating factor. After 24 hours of continuous stimulation, the mRNA expressions of genes Col1a1, TGFβ1 and CTGF were detected, as shown in Figure 2. Fig.12 shown.
[0124] Example 7
[0125] In this example, the inhibitory effect of the micropeptide HMBJ on a human pulmonary fibrosis cell model was detected.
[0126] The human non-small cell lung cancer cell line A549 was cultured in a cell culture incubator at 37°C and 5% CO2 until the cell density was above 80%. The cells were collected by trypsin digestion, centrifuged and discarded the supernatant. The cells were resuspended in complete medium and counted using a cell counter. The cell concentration was adjusted to 1.5×10 5After the cells were cultured for 24 hours, the culture medium was removed and 2‰ DMSO solvent was added as a negative control and 2μmol of Nintedanib was added as a positive control. The other groups were added with 40μmol, 10μmol, 2.5μmol, 625nmol and 156nmol of synthetic peptide HMBJ in equal proportions as the drug-dosing group. Half an hour later, except for the blank control, the other groups were added with 10nmol of recombinant human TGFβ1 (Peprotech) stimulating factor. After 24 hours of continuous stimulation, the mRNA expressions of genes Col1a1, TGFβ1 and CTGF were detected. Fig.13 shown.
Claims
1. A novel micropeptide HMBJ, characterized in that: The novel micropeptide HMBJ contains the amino acid sequence shown in SEQ ID NO.
3.
2. A nucleotide, characterized in that The nucleotide encodes a novel micropeptide HMBJ as described in claim 1.
3. A nucleotide according to claim 2, characterized in that The nucleotide sequence includes the lncRNA molecule ENSG00000272654 and / or the ORF contained therein. The nucleotide sequence of the lncRNA molecule ENSG00000272654 is shown in SEQ ID NO.1; the nucleotide sequence of the ORF contained in the lncRNA molecule ENSG00000272654 is shown in SEQ ID NO.
2.
4. Use of a nucleotide according to claim 3 in the preparation of a reagent for diagnosing or assisting in the diagnosis of organ fibrosis, wherein the organ fibrosis includes liver fibrosis, kidney fibrosis and / or lung fibrosis.
5. Use of a nucleotide according to claim 4 in preparing a reagent for diagnosing or assisting in diagnosing organ fibrosis, characterized in that: The diagnostic or auxiliary diagnostic reagent for organ fibrosis includes primers for specifically amplifying the lncRNA molecule ENSG00000272654 or the ORF contained therein.
6. A recombinant vector, characterized in that: The recombinant vector contains the nucleotide according to claim 2 or 3.
7. Use of a novel micropeptide HMBJ according to claim 1, a nucleotide according to claim 2 or 3, or a recombinant vector according to claim 6 in the preparation of a drug for treating or assisting in treating organ fibrosis, wherein the organ fibrosis includes liver fibrosis, kidney fibrosis and / or lung fibrosis.
8. A pharmaceutical composition for treating or assisting in treating organ fibrosis, characterized in that: The pharmaceutical composition contains at least the novel micropeptide HMBJ according to claim 1, or the nucleotide according to claim 2 or 3, or the recombinant vector according to claim 6, and a pharmaceutically acceptable carrier.
9. A kit for diagnosing or assisting in the diagnosis of organ fibrosis, characterized in that: The kit contains a specific primer pair for the nucleotide sequence of claim 3.
10. A kit for diagnosing or assisting in the diagnosis of organ fibrosis according to claim 9, characterized in that: The specific primer pair contains the following nucleotide sequence: F:CAAGGGATGGAGGCGAAACT; R:CCACAGTGCTGGTCAAGTCA.
